VEGFA and neoplasm: During chemotherapy, antiangiogenic agents such as bevacizumab neutralize vascular endothelial growth factor (VEGF) and curb tumor neovascularization.[19] While this transiently “normalizes” aberrant vessels, it simultaneously undermines the integrity of native vasculature.